



Radio Nuclide Therapy: From Molecular to Cure

Guest Editor:

Dr. Carlo Aprile

Nuclear Medicine Unit, IRCCS
Fondazione Policlinico San
Matteo, I-27100 Pavia, Italy

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

After the introduction of radioiodine therapy for thyrotoxicosis and differentiated thyroid cancer in the middle of the last century, radionuclide therapy (RNT) underwent an enormous development exploring innovative ways.

Despite this, RNT faces many challenges and limitations:

- A molecular vector with high affinity and specificity for the tumor target;
- A nuclide, preferable a true theranostic, with the emission and effective half-life fitting with uptake rate and residence in the target;
- The chelator and cages;
- Nanogenerators;
- tumor cells kinetics and metabolism;
- cell radiobiology;
- Combined use with chemotherapeutics, biological drugs and EBRT, beta and alpha sequence.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI